30th European Hematology Association Annual Congress to Feature Nine Analysis Group Outcomes Research Presentations

June 6, 2025

Analysis Group consultants will present research from nine distinct studies as part of the European Hematology Association Annual Congress (EHA2025), which will take place from June 12 to 15, 2025, in Milan, Italy.

The firm’s studies will be exhibited in the Poster Hall at Allianz MiCo, the largest convention center in Europe. EHA2025 attendees will be introduced to Analysis Group’s research on the following diseases:

Acute Myeloid Leukemia

  • “Healthcare resource utilization in newly diagnosed patients with acute myeloid leukemia treated with venetoclax compared to high- and low-intensity non-venetoclax therapies,” scheduled on June 14, 6:30–7:30 p.m. CEST.
    • Coauthors include: Managing Principal Annie Guérin, Manager Rebecca Burne, Associate Kaitlyn Easson, Senior Research Professional Mohira Levesque-Leroux, Research Professional Eugene Baraka, and researchers from Weill Cornell Medicine, Dana-Farber Cancer Institute, The University of North Carolina at Chapel Hill, Rabin Medical Center, Duke University School of Medicine, the Medical College of Wisconsin, The University of Alabama at Birmingham, Moffitt Cancer Center, Tel Aviv Sourasky Medical Center, University of Colorado School of Medicine, Medstar Georgetown University Hospital, Montefiore Einstein Comprehensive Cancer Center, Hebrew University of Jerusalem, Sunnybrook Health Sciences Centre Odette Cancer Program, Scripps Cancer Center, Rambam Health Care Campus, AbbVie, Genentech, and Memorial Sloan Kettering Cancer Center. Funding for this study was provided by AbbVie and Genentech.
  • “Real-world patient management practices in responders to venetoclax for newly diagnosed acute myeloid leukemia,” scheduled on June 13, 6:30–7:30 p.m. CEST.
    • Coauthors include: Manager Rebecca Burne and researchers from Rabin Medical Center, Weill Cornell Medicine, Dana-Farber Cancer Institute, The University of North Carolina at Chapel Hill, Duke University School of Medicine, the Medical College of Wisconsin, The University of Alabama at Birmingham, Moffitt Cancer Center, Tel Aviv Sourasky Medical Center, University of Colorado School of Medicine, University of Pennsylvania, Montefiore Einstein Comprehensive Cancer Center, Hebrew University of Jerusalem, Sunnybrook Health Sciences Centre Odette Cancer Program, Scripps Cancer Center, Rambam Health Care Campus, AbbVie, Genentech, Memorial Sloan Kettering Cancer Center, and Medstar Georgetown University Hospital. Funding for this study was provided by AbbVie and Genentech. 
  • “Outcomes of Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine in Real-World Belgian Clinical Practice,” scheduled on June 14, 6:30–7:30 p.m. CEST.
    • Coauthors include: Manager Rebecca Burne and researchers from CHU de Liège, Memorial Sloan Kettering Cancer Center, Hôpital de Jolimont, Universitair Ziekenhuis Brussel, AbbVie, and Universitaire Ziekenhuizen Leuven. Funding for this study was provided by AbbVie.

Chronic Lymphocytic Leukemia

  • “Treatment Effectiveness in Patients (Pts) with Chronic Lymphocytic Leukemia (CLL) Receiving Venetoclax-Based Therapy After Progression on a Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi),” scheduled on June 14, 6:30–7:30 p.m. CEST. 
    • Coauthors include: Managing Principal Annie Guérin, Vice President Irina Pivneva, Associate Talissa Watson, and researchers from Université de Montréal; Cleveland Clinic; University of Oxford; Fred Hutchinson Cancer Center; AbbVie; Dana-Farber Cancer Institute; Columbia University; University of California, Irvine; Atrium Health Levine Cancer Institute; John Theurer Cancer Center, Hackensack Meridian Health; Mayo Clinic; Nottingham University Hospitals NHS Trust; University of Rochester Medical Center; Rutgers Cancer Institute of New Jersey; Novant Health Cancer Institute; University of Massachusetts; Dartmouth Hitchcock Medical Center; Tufts Medical Center; The University of North Carolina at Chapel Hill; Stanford University; Memorial Sloan Kettering Cancer Center; University of Pennsylvania; Lowell General Hospital; and Emory University. Funding for this study was provided by AbbVie.
  • “The Economic Impact of Treatment Sequences for Chronic Lymphocytic Leukemia (CLL) in Italy: A Cost of Care Sequencing Model for Patients with CLL,” scheduled on June 14, 6:30–7:30 p.m. CEST.
    • Coauthors include: Managing Principal Annie Guérin, Managers Nisha Hazra and Honghao Fang, Senior Analyst Weiye Chen, and researchers from Università di Padova, Azienda Ospedaliera Universitaria (AOU), AbbVie, UOC di Oncoematologia, Ospedali Riuniti Villa Sofia, and Università Cattolica del Sacro Cuore. Funding for this study was provided by AbbVie.

Chronic Myeloid Leukemia 

  • “Asciminib after One Prior Tyrosine Kinase Inhibitor in Patients with Chronic Myeloid Leukemia – a Physician Panel-Based Chart Review Study in the United States,” scheduled on June 13, 6:30–7:30 p.m. CEST.
    • Coauthors include: Analysis Group Managing Principal Annie Guérin, Vice President Dominick Latrémouille-Viau, Manager Carmine Rossi, Senior Research Professional Remi Bellefleur, and researchers from Novartis and the Medical College of Wisconsin. Funding for this study was provided by Novartis.
  • “Patient-physician communication regarding TKI-related adverse events and their impact on quality of life in CML – Insights from patient and physician surveys in the US,” scheduled on June 14, 6:30–7:30 p.m. CEST.
    • Coauthors include: Managing Principal Annie Guérin, Vice President Dominick Latrémouille-Viau, Manager Nisha Hazra, Associate Yan Meng and researchers from the Medical College of Wisconsin; University of California, San Francisco; The Leukemia & Lymphoma Society; CML Buster Foundation; Ipsos; and Novartis. Funding for this study was provided by Novartis.
  • “Impact of adverse events on quality of life in chronic myeloid leukemia (CML) – Results from the patient survey on humanistic burden of intolerance to first or second TKIs (SHIFT) study in the US,” scheduled on June 14, 6:30–7:30 p.m. CEST.
    • Coauthors include: Managing Principal Annie Guérin, Vice President Dominick Latrémouille-Viau, Manager Nisha Hazra, Associate Yan Meng, and researchers from University of California, San Francisco; CML Buster Foundation; The Leukemia & Lymphoma Society; Novartis; Ipsos; and the Medical College of Wisconsin. Funding for this study was provided by Novartis.
  • “Quality of Life and Work Impacts among Caregivers of Patients with Chronic Myeloid Leukemia (CML) – A Caregiver Survey in the US,” scheduled on June 14, 6:30–7:30 p.m. CEST.
    • Coauthors include: Managing Principal Annie Guérin, Vice President Dominick Latrémouille-Viau, Manager Nisha Hazra, Associate Yan Meng, and researchers from University of California, San Francisco; CML Buster Foundation; The Leukemia & Lymphoma Society; Novartis; Ipsos; and the Medical College of Wisconsin. Funding for this study was provided by Novartis.

Learn more about EHA2025